Page last updated: 2024-12-07

amiprophos methyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

amiprophos methyl: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID100524
CHEMBL ID1256629
SCHEMBL ID116428
MeSH IDM0068888

Synonyms (55)

Synonym
amiprofos-methyl
nsc313446
ntn 2975
phosphoramidothioic acid, o-methyl o-(2-nitro-p-tolyl) ester
ntn 6867
o-methyl 2-nitro-4-tolyl isopropylphosphoramidothioate
36001-88-4
nsc-313446
phosphoramidothioic acid, o-methyl o-(4-methyl-2-nitrophenyl) ester
tokunol m
phosphoramidothioic acid, (1-methylethyl)-, o-methyl o-(4-methyl-2-nitrophenyl) ester
brn 2000833
o-methyl o-(4-methyl-2-nitrophenyl) (1-methylethyl)phosphoramidothioate
amiprophos methyl
o-methyl o-(4-methyl-6-nitrophenyl)-n-isopropylphosphorothioamidate
einecs 252-829-4
o-methyl o-(4-methyl-2-nitrophenyl) isopropylthiophosphoramidate
amiprofos-methyl [iso]
bay ntn6867
ntn 80
bay ntn80
nsc 313446
phosphoramidothioic acid, n-isopropyl-, o-methyl o-(2-nitro-p-tolyl) ester
amiprophosmethyl
amide amiprophos-methyl
n-[methoxy-(4-methyl-2-nitro-phenoxy)phosphinothioyl]propan-2-amine
n-[methoxy-(4-methyl-2-nitrophenoxy)phosphinothioyl]propan-2-amine
NCGC00248337-01
tox21_301206
dtxcid2021600
NCGC00255103-01
dtxsid4041600 ,
cas-36001-88-4
CHEMBL1256629
unii-d130e8v1on
d130e8v1on ,
amiprofos methyl
amiprophos-methyl
bay-ntn 6867
(+/-)-amiprofos-methyl
amiprofos-methyl, (+/-)-
(rs)-(o-methyl o-2-nitro-p-tolyl isopropylphosphoramidothioate)
o-(2-nitro-4-methylphenyl) o-methyl n-isopropylphosphoramidothioate
o-methyl o-(4-methyl-2-nitrophenyl) n-(1-methylethyl)phosphoramidothioate
o-methyl o-4-methyl-2-nitrophenyl n-isopropylphosphoramidothioate
bay-ntn 80
SCHEMBL116428
amiprofos methyl, pestanal(r), analytical standard
55840-20-5
o-methyl o-4-methyl-2-nitrophenyl isopropylphosphoramidothioate
Q27275963
D96005
HY-111939
CS-0094157
AKOS040754654
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency48.55770.006038.004119,952.5996AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency9.68850.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency48.76360.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency30.63790.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency8.63070.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency7.69590.000417.946075.1148AID1346795
retinoid X nuclear receptor alphaHomo sapiens (human)Potency21.87240.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency23.45430.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency30.63790.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency18.49540.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743079; AID743080; AID743091
aryl hydrocarbon receptorHomo sapiens (human)Potency14.86980.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency54.48270.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency67.29850.001628.015177.1139AID1224843; AID1224895
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency17.22890.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency17.22890.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID522812Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235T mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522811Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235L mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522816Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243S mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522810Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin L136F mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522814Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin T239I mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID622163Antimalarial activity against Plasmodium falciparum 3D7 infected in O-positive human erythrocytes assessed as inhibition of parasite lactate dehydrogenase after 72 hrs by pLDH method2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Synthesis and evaluation of phosphoramidate and phosphorothioamidate analogues of amiprophos methyl as potential antimalarial agents.
AID522807Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin S6I mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID753371Antimalarial activity against Plasmodium falciparum 3D7 infected in O positive erythrocytes assessed as parasite lactate dehydrogenase activity after 72 hrs2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Synthesis and evaluation of phenoxyoxazaphospholidine, phenoxyoxazaphosphinane, and benzodioxaphosphininamine sulfides and related compounds as potential anti-malarial agents.
AID522809Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin H28Q mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522808Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin F24H mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522815Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243C mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522806Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin V4L mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522813Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235V mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522805Antimicrobial activity against Toxoplasma gondii RH infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (22.22)18.7374
1990's7 (25.93)18.2507
2000's9 (33.33)29.6817
2010's4 (14.81)24.3611
2020's1 (3.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.70 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index22.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]